期刊文献+

我院2011-2013年抗肿瘤药使用分析 被引量:1

Analysis of the Utilization of Antitumor Drugs in Our Hospital from 2011 to 2013
原文传递
导出
摘要 目的:了解我院抗肿瘤药的使用情况及趋势。方法:结合我院肿瘤分类构成情况,采用用药频度(DDDs)和金额排序法对2011-2013年我院抗肿瘤药的应用情况进行分析。结果:各年度肺癌、乳腺癌、食管癌构成排序均居前3位。植物来源的抗肿瘤药及其衍生物、抗代谢药和其他抗肿瘤药各年度销售金额均居前3位,约占总销售金额的80%;多西他赛、紫杉醇销售金额连续3年均居前3位;各年度DDDs排序前3位均为卡培他滨、替吉奥、氟尿嘧啶。结论:我院抗肿瘤用药倾向于抗代谢药,而紫杉烷类、铂类应用也较多,但分子靶向药品种少、市场份额小。 OBJECTIVE: To investigate the application and trend of antitumor drugs in our hospital. METHODS: Combined with the composition of tumor, the utilization of antitumor drugs in our hospital from 2011 to 2013 was analyzed statistically in terms of consumption sum and DDDs. RESULTS: Top 3 tumors in the list of composition ranking were lung cancer, breast cancer and esophageal cancer for 3 consecutive years. Top 3 drugs varieties in the list of consumption sum were antitumor drug and its de- rivative, antimetabolites and other antitumor drug, which accounted for nearly 80% of total consumption sum. Docetaxel and pacli- taxel occupied the first 3 places in the list of consumption sum in 3 years. Top 3 drugs in the list of DDDs were capecitabine, S-1 and fluorouracil. CONCLUSIONS: Medication regimen tends to antimetabolites, while platinum and taxanes are used frequently. But the targeted drug is poor in variety and market share.
出处 《中国药房》 CAS CSCD 2014年第46期4325-4328,共4页 China Pharmacy
关键词 闽南地区 抗肿瘤药 销售金额 用药频度 日均费用 Southern Fujian Antitumor drugs Consumption sum DDDs DDC
  • 相关文献

参考文献15

  • 1疑夕.2013年FDA批准的27个新药汇总[EB/OL].[2014-03-15].http://yao.dxy.cn/article/66042.
  • 2陈新谦,金有豫,汤光.新编药物学[M].17版.北京:人民卫生出版社,2011:3465.
  • 3中国国家处方集编委会.中国国家处方集[M].北京:人民军医出版社,2010:810.
  • 4程建娥,张藜莉,李影,申丽萍.我院2007-2009年抗肿瘤药及其中《中国国家处方集》遴选药物使用情况分析[J].中国药房,2011,22(44):4192-4195. 被引量:2
  • 5刘红,宁华,巩红,焦园园,张艳华.全国9家肿瘤专科医院2010年抗肿瘤药利用分析[J].中国药房,2011,22(46):4343-4346. 被引量:4
  • 6Benson AB, Bekaii-Saab T, Chan E, et al. Rectal cancer [J]. J Natl Compr Canc Netw, 2012,10 (12):1 528.
  • 7Ajani JA, Bentrem D J, Besh S, et al. Gastric cancer, ver- sion 2.2013: featured updates to the NCCN guidelines [J]. J Natl Compr Canc Netw , 2013,11 (5) : 531.
  • 8张宁宁,郭晓钟.S-1在消化道肿瘤中的治疗作用[J].中国新药杂志,2010,19(19):1774-1777. 被引量:6
  • 9Fujitani K. Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East [J]. Dig Surg, 2013,30(2) : 119.
  • 10Peters S, Adjei AA, Gridelli C, et al. Metastatic non- small-cell lung cancer(NSCLC) :ESMO clinical practice guidelines for diagnosis treatment and follow-up[J]. Ann Oncol,2012,23(Suppl 7) :56.

二级参考文献39

共引文献1200

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部